Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab and Cyclosporine in Active Psoriasis
NCT00050648Phase 2Completed
- Sponsor
- The Rockefeller University
- Start
- Oct 1997
- Primary completion
- Sep 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daclizumab in Psoriasis vulgaris (PV), sponsored by The Rockefeller University. Started Oct 1997; status: completed.
02
Drugs
daclizumab
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT00050648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050648.